Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now

finance.yahoo.com · 2026-09-07

Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.

TickrTrends take: Pfizer's valuation is currently assessed as overvalued by TickrTrends, which suggests that investors focusing on fundamental value metrics may want to examine whether near-term catalysts justify the present pricing before committing capital. For Healthcare sector investors evaluating PFE, the key consideration is whether any operational or pipeline developments cited in recent commentary can narrow the gap between current market valuation and intrinsic value estimates. Valuation-conscious readers should monitor whether PFE's fundamentals strengthen enough to support its current price levels or if the stock experiences a correction toward more historically typical valuations for the sector.

Read the full story at finance.yahoo.com →